Pakistan has won an award for best poster presentation on research about simultaneous treatment of Hepatitis C in patients undergoing treatment of blood cancer (leukemia). In children prevailing practice is not to treat hepatitis C till the treatment of blood cancer is over, particularly in children. Not treating Hepatitis C in children less than 16 years was recommended by the Food and Drug Administration of USA.
In Pakistan Hepatitis C in children is common when the blood cancer is diagnosed, and during treatment of blood cancer their liver function deteriorate and treatment of cancer is stopped till the liver functions improve. Even after successful treatment of cancer a number as they come from far off places ignore treatment of Hepatitis C.
In a trial preliminary report presented at the Asia section of International Society of Pediatric Oncology held at Abu Dhabi from 3rd to 6th April 2019, a combinations of antiviral drugs is used in the age group 3 years to 12 years with successful results by Dr Uzma Imam Head of Pediatric Oncology at the cancer centre of Child Aid Association at NICH Karachi.
Her poster presentation was judged as third after the first and second from China and Russia among 70 poster presentation. There were 350 participants at the congress.-PR
Comments
Comments are closed.